THE WOODLANDS, Texas, Sept. 7, 2011 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today reported results from the lowest three doses of its ongoing Phase II study of oral Proellex assessing the drug's ability to stop menses while not affecting liver function. The rigorously designed study evaluates the impact of the drug on menstrual events, the primary efficacy measure, as well as liver function, the primary safety assessment.
